.png){kind=icon}
返回
Y
Yohann Loriot
Université Paris-Saclay
76H指数
1.1K论文数
5.4W被引数
收录论文 305
发表时间
.png){kind=icon}
A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastasesEORTC 1333/PEACE-3研究的通俗摘要：恩扎卢胺单药与恩扎卢胺联合镭-223治疗伴有骨转移的转移性去势抵抗性前列腺癌（mCRPC）患者的比较研究.png)
FUTURE ONCOLOGY.png)
FUTURE ONCOLOGYIF2.6
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tractTROPiCS-04研究的通俗语言摘要：沙西妥珠单抗在铂类化疗和免疫疗法之后，用于患有膀胱、尿道或上尿路局部晚期或转移性癌症的人群FUTURE ONCOLOGY
FUTURE ONCOLOGYIF2.6
PREAI
分享收藏A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapyTROPHY-U-01研究（队列2）的通俗总结：在无法接受顺铂为基础化疗的转移性尿路上皮癌患者中，免疫疗法后使用sacituzumab govitecan的疗效。FUTURE ONCOLOGY
OAAI
FUTURE ONCOLOGYIF2.6
OAAI分享收藏Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study恩诺单抗维多汀联合帕博利珠单抗对比化疗在先前未经治疗的局部晚期或转移性尿路上皮癌患者中的疗效（EV-302）：一项开放标签、随机对照、III期研究的患者报告结局
PREAI
分享收藏Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti’s Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051–60回复Francesco Montorsi、Giorgio Gandaglia、Francesco Barletta和Alberto Briganti致编辑的信：Bertrand F. Tombal、Francisco Gomez-Veiga、Alvaro Gomez-Ferrer等人的一项关于口服达罗他胺单药治疗与雄激素剥夺疗法在激素敏感性前列腺癌男性患者中的比较研究（II期随机开放标签研究）（EORTC-GUCG 1532）。《欧洲泌尿肿瘤学》2024；7：1051–60。
PREAI
分享收藏